Immuron Limited (NASDAQ:IMRN) saw its shares jumped Friday, on announcing a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials.
The studies were conducted independently by the Hadassah Medical Center, Israel.
The research findings were recently published on the October 1, in the Journal Drug Development Research entitled Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention and treatment of COVID-19. The paper examines the ability of IMM-124E to promote antiviral interferon-γ (IFNγ) T cell responses in a preclinical mouse model and in a phase I/IIa clinical study conducted in 5 human health volunteers.
IMM124E is used to manufacture Immuron’s flagship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn.
The paper examines the ability of IMM-124E to promote antiviral interferon-γ (IFNγ) T cell responses in a mouse model and five healthy human volunteers.
The research study aimed to determine the ability of IMM-124E to promote antiviral interferon γ (IFNγ) T cell responses.
In the preclinical study, data showed that IMM124E enhanced antiviral immunity across the viral strains tested. A similar response was observed in the human study.
Healthy volunteers received IMM-124E orally, at a daily dose of 600 mg for four consecutive days and 1200 mg for an additional day.
The preliminary clinical data suggested a similar effect in humans in augmenting antiviral responses against COVID-19 and Hepatitis B.
Immuron previously reported research investigations on IMM-124E demonstrated neutralizing activity against COVID-19 infection.
IMRN stock is up 21 cents, or 6% at $3.73 first thing Friday.